Ligand id: 8309

Name: decernotinib

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 95.59
Molecular weight 392.16
XLogP 3.27
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Decernotinib reached Phase III clinical trial as a potential treatment for rheumatoid arthritis (RA), but development appears to have been terminated, apparently for strategic reasons.
Mechanism Of Action and Pharmacodynamic Effects
Inhibition of JAK3 mediates signalling via a small subset of cytokine receptors, with which JAK3 (and JAK1) associate. These include the receptors for IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 which share a common γ receptor chain. Partial or reversible inhibition of JAK3 provides effective modulation of the immune activity in conditions such as autoimmune disorders.